Contribution of VKORC1 and CYP2C9 polymorphisms in the interethnic variability of warfarin dose in Malaysian populations

Annals of Hematology

Volumn 90, Issue 6, 2011, Pages 635-641

  Gan, Gin Gin ^a   Phipps, Maude E ^b   Lee, Michael M T ^c   Lu, Liang S ^c   Subramaniam, Rajallectchumy Y ^d   Bee, Ping C ^d   Chang, Sean H ^e  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b MONASH UNIVERSITY MALAYSIA   (Malaysia)

^c INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^d UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

^e QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

CYP2C9; Gene polymorphisms; Indians; VKORC1; Warfarin

Indexed keywords

WARFARIN;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; CHINESE; CONTROLLED STUDY; CYP2C9 GENE; ETHNIC DIFFERENCE; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; INDIAN; MAJOR CLINICAL STUDY; MALAYSIA; MALE; PRIORITY JOURNAL; VKORC1 GENE;

ADULT; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHNIC GROUPS; FEMALE; GENETICS, POPULATION; GENOTYPE; HEART DISEASES; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; INDIA; MALAYSIA; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PULMONARY EMBOLISM; WARFARIN;

EID: 79956119832     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-010-1119-6     Document Type: Article

References (45)

1. Aquilante CL, Langaee TY, Lopez LM, Yarandi HN, Tromberg JS, Mohuczy D et al (2006) Influence of conagulation factor, vitamin K epoxide reductase complex subunit 1, cytochrome P450 2C9 gene polymorphisms on warfarin dose requirement. Clin Pharmacol Ther 79:291-302
2. Beyth RJ, Quinn L, Landefeld CS (2000) A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomised controlled trial. Arch Intern Med 133:687-695
3. Bodin L, Verstuyft C, Tregouet DA, Robert A, Dubert L, Funck-Brentano C et al (2005) Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1)genotypes as determinants of acenocoumarol sensitivity. Blood 106:135-140 (Pubitemid 40967184)
4. Dang MT, Hambledon J, Kayser SR (2005) The influence of ethnicity on warfarin dosage requirement. Ann Pharmacother 39:1008-1012
5. D'Andrea G, D'ambrosio DG, Di Pema P et al (2005) A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105:645-649
6. Douketis JD, Foster GA, Crowther MA, Prins MH, Ginsberg JS (2000) Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Arch Intern Med 160:3431-3436
7. Fihn SD et al (1993) Risk factors for complications for chronic anticoagulation. A multicenter study. Warfarin optimised outpatient follow up study group. Ann Intern Med 118:511-520
8. Gage BF, Eby C, Johnson JA, Deych E, Reider MJ, Ridker PM, Milligan PE, Grice G, Lenzini P, Rettie AE, Aquilante CL, Grosso L, Marsh S, Langaee T, Farnett LE, Voora D, Veenstra DL, Glynn RJ, Barrett A, McLeod HL (2004) Use of pharmacogenetics and clinical factors to predict themaintenance dose of warfarin. Thromb Haemost 91:87-94 (Pubitemid 38111225)
9. Gage BF, Eby CS (2003) Pharmacogenetics and anticoagulant therapy. J Thromb Thrombolysis 16:73-78 (Pubitemid 38477228)
10. Geisen C, Watzka M, Sittinger K et al (2005) VKORC1 haplotypes and its impact on the inter-individual and inter-ethnic variability of oral anticoagulation. Thromb Haemost 94:773-779 (Pubitemid 41489236)
11. Gan GG, Goh KY, Chong HT, Pang KW (2003) Racial background is one of the determinant factors in the maintenance dosage of warfarin. Int J Hematol 78:84-86 (Pubitemid 36899909)
12. Gan GG, Ku CS, Phipps M, Sangkar JV, Teh A (2004) Genetic polymorphism in warfarin maintenance doses-letter to editor. Int J Hematol 80:295-296 (Pubitemid 39410940)
13. Gurwitz J, Avorn J, Ross-Degnan D, Choodnovskiy I, Ansell J (1992) Aging and the anticoagulant response to warfarin therapy. Ann Intern Med 116:901-904 (Pubitemid 23034781)
14. Jonas DE, McLeod HL (2009) Genetic and clinical factors relating to warfarin dosing. Trends Pharmacol Sci 30:375-386
15. Kamali F (2006) Genetic influences on the response to warfarin. Curr Opin Hematol 13:357-361
16. Lal S, Sandamaraj E, Jada SR, KongMC, Lee LH, Goh BC, Lee SC, Chowbay B (2007) Influence of APOE gene and VKORC1 haplotypes on warfarin requirements in Asian patients. Br J Clin Pharmacol 65:260-264
17. Lee CR, Goldstein JA, Pieper JA (2002) Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in vitro and human data. Pharmacogenetics 12:251-263 (Pubitemid 34596790)
18. Lee MTM, Chen CH, Chuang HP, Lu LS, Chou CH, Wen MS et al (2009) VKORC1 haplotypes in five East Asian populations and Indians. Pharmacogenomics 10:1209-1216
19. Lee MTM, Chen CH, Chou CH, Lu LS, Chuang HP, Chen YT et al (2009) Genetic determinants of warfarin dosing in the Han-Chinese population. Pharmacogenomics 10:1905-1913
20. Lee SC, Oldernburg J, Chong PY, Rost S, Guo JY, Yap HL et al (2006) Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population. Clin Pharmacol Ther 79:197-205
21. Li T, Lange LA, Li X, Susswein L, Bryant B, Malone R, Lange EM, Huang TY, Stafford DW, Evans JP (2006) Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulaition. J Med Genet 43:740-744 (Pubitemid 44483917)
22. Limdi NA, Weiner H, Goldstein JA, Acton RT, Beasley TM (2009) Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy. Blood Cells Mol Dis 43:119-128
23. Lindh JD, Holm L, Andersson ML, Rane A (2009) Influence of CYP2C9 genotype on warfarin dose requirements-a systemic review and metaanalysis. Eur J Clin Pharmacol 65:365-375
24. Marsh S, King CR, Porche-Sorbet RM, Scott-Horton TJ, Eby CS (2006) Population variation in VKORC1 haplotype structure. J Thromb Haemost 4(2):473-474
25. Miao L, Yang J, Huang C, Shen Z (2007) Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulation response to warfarin. Proposal for a new dosing regimen in Chinese Patients. Eur J Clin Pharmacol 63:1135-1141 (Pubitemid 350112769)
26. Montes R, Gaona ER, Martinez-GonzalezMA, Alberca I, Hermida J (2006) The c.-1639G>A polymorphims of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients. Br J Haematol 133:183-187
27. Meckley LM, Wittkowsky AK, Reider MJ, Rettie AE, Veenstra DL (2008) An analysis of the relative effect of VKORC1 and CYP2C9 variants on anticoagulation related outcome in warfarin-treated patients. Thromb Haemost 100:229-239
28. Ngow HA, Wan Khairina WMN, Teh LK, Lee WL, Harun R, Ismail R, Salleh MZ (2009) CYP2C9 polymorphism: prevalence in healthy and warfarin treatend Malay and Chinese in Malaysia. Singapore Med J 50:490-493
29. Obayahsi K, Nakamura K, Kawana J, Ogata H, Hanada K, Kurabayashi M et al (2006) VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients. Clin Pharmacol Ther 80:169-178 (Pubitemid 44160690)
30. Reider MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE (2005) Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352:2285-2293 (Pubitemid 40740552)
31. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P et al (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106:2329-2333 (Pubitemid 41510803)
32. Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Frye-Anderson A et al (2008) Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 358:999-1008 (Pubitemid 351347099)
33. Scott SA, Khasawneh R, Peter I, Kornreich R, Desnick RJ (2010) Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. Pharmacogenomics 11:781-791
34. Takahashi H, Wilkinson GR, Nutescu EA, Morita T, Ritchie MD, Scordo MG et al (2006) Different contributions of polymorphism in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics 16:101-110 (Pubitemid 43145678)
35. Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N et al (2005) A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 5(3):e100043
36. Tham LS, Goh BC, Nafziger A, Guo JY,Wang LZ, Soong R, Lee SC (2006) Awarfarin dosing model in Asians that uses single nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9. Clin Pharmacol Ther 80:346-355 (Pubitemid 44479750)
37. Veenstra DL (2005) Chen G, Rettie AE. Association of vitamin K epoxide reductase complex 1 (VKORC1) variants in a Hong Kong Chinese population. Pharmacogenet Genomics 15:687-691
38. Visser LE, Trienekens PH, De Smet PAGM et al (2005) Patients with an APOEε4 allele require lower doses of coumarin anticoagulants. Pharmacogenetics 15:69-74 (Pubitemid 40562983)
39. Wadelius M, Chen L, Eriksson N, Bumpstead S, Ghori J, Wadelius C, Bentley D, Mcginnis R et al (2007) Association of warfarin dose with genes involved in its action and metabolism. Hum Genet 121(1):23-34 (Pubitemid 46421137)
40. Wadelius M, Pirmohamed M (2007) Pharmacogenetics of warfarin: current status and future challenges. Rev Pharmacogenomics J 7 (2):99-111 (Pubitemid 46567142)
41. Wadelius M, Chen L, Lindh J, Eriksson N, Ghori MJ, Bumpstead S, Holm L, Mcginnis R, Rane A, Deloukas P (2009) The largest prospective warfarin-treated cohorts supports genetic forecasting. Blood 113(4):784-792
42. Yuan HY, Chen JJ, Lee MT, Wung JC, Chen YF, Chang MJ, Lu MJ, Hung CR, Wei CY, Chen CH, Wu JY, Chen YT (2005) A novel functional VKORC1 Promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 14:1745-1751 (Pubitemid 41430097)
43. Yuen E, Gueorguieva I, Wise S, Soon D, Aarons L (2010) Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin. J Pharmacokinet Pharmacodyn 37:3-24
44. Zhao F, Loke C, Rankin SC, Guo JY, Lee HS, Wu TS, Tan T et al (2004) Novel CYp2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin Pharmacol Ther 76:210-219 (Pubitemid 39221795)
45. Zainuddin Z, Teh LK, Suhaimi AWM, Ismail R (2006) Malaysian Indians are genetically similar to Caucasians: CYP2C9 polymorphism. J Clin Pharm Clin Ther 31:187-191